Nicotinic acetylcholine receptors (nAChR) are expressed on bronchial epithelial and non-small cell lung cancer cells and are involved in cell growth regulation. Nicotine (classical nAChR agonist) induced cell proliferation, whereas nAChR antagonists, dtubocurarine or a-cobratoxin (a-CbT), induced cell death. In the current study, we further explored the antitumor potential mechanisms and activities of a-CbT. NOD/SCID mice were grafted intraperitoneally or orthotopically and treated with a-CbT. a-CbT treatment [0.04 ng/kg or 0.12 ng/kg] induced a strong reduction in tumor size (90%) in comparison with mice treated with the vehicle alone. Tumor inhibition was related to severe induction of apoptosis. Moreover, neoangiogenesis was strongly inhibited (reduction of cells positive to vascular endothelial growth factor and CD31). Biochemical analyses of the cells, isolated by the primary lung tumor in a-CbT-treated mice, showed apoptosis features characterized by: (i) inhibition of BAD phosphorylation at Ser 112 and Ser
136; (ii) BAD dissociation from 14-3-3; (iii) BAD association with BCL-XL; and (iv) cleavage of caspase-9. Moreover, these cells were unable to grow in soft agar and develop tumor, when reinjected into mice. The small interfering RNA-mediated silencing of the a7-nAChR gene confirmed that a-CbT specifically inhibited the a7-nAChR-mediated survival pathway in A549 cells. Furthermore, the specificity of a-CbT is reinforced by the lack of effect of short chain toxin (Erabutoxin-a). Once more, the no effect of the low-affinity R33E-modified a-CbT strengthened the specificity of this inhibition. Although a7-nAChR antagonists, such as a-CbT, are unlikely to be a primary therapy, it may provide lead compounds for the design of clinically useful drugs. '
UICCKey words: nicotinic acetylcholine receptors; cobratoxin; mouse model lung cancer; tumor-induced apoptosis; neoangiogenesis inhibition Lung cancer is the leading cause of cancer mortality worldwide. Epidemiologic studies have demonstrated that cigarette smoking is the major risk factor in its development, with a striking doseresponse relationship. It is estimated that 80-90% of lung cancer incidence can be attributed to cigarette smoking.1 Despite years of research, the prognosis for patients with lung cancer remains dismal, with a 5-year survival rate of 14%. Currently, the usual chemotherapy regimen (adjuvant or neoadjuvant) combines a platinum-containing drug with another cytotoxic agent (i.e., gemcitabin, Taxol or navelbine). However, platinum-based therapies have drawbacks: severe toxic effects for the patient and drug resistance in the tumor cells.2 Future directions for treatment are heavily weighted toward targeted therapies, namely those aimed at molecular abnormalities involved in the pathogenesis of lung cancer 3 rather than traditional cytotoxic agents. 4 Currently, it has been established that acetylcholine (ACh) is widely synthesized by a variety of non-neuronal cell types, including airway epithelial cells. [5][6][7][8][9][10][11][12][13][14...